Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology, admits that he was once “oblivious” to his patients’ concerns about the cost of cancer treatment. However, it is important for clinicians to empathize with these fears and understand how they can factor into a patient’s care choices.
Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology, admits that he was once “oblivious” to his patients’ concerns about the cost of cancer treatment. However, it is important for clinicians to empathize with these fears and understand how they can factor into a patient’s care choices.
Transcript (slightly modified)
How does cost sharing influence outcomes in oncology?
This is a fascinating question, because I’ll tell you that for years, actually decades, patients have asked me, “What does this cost?” And I’ve been completely oblivious to that answer. And over the last 5 years I’ve realized that me being oblivious to the cost of care was inadequate because for some patients, this idea that either through tiered co-payments or even through co-insurance, that part of the cost of that care, which could in fact be quite substantial, was theirs, was going to be borne by them.
So when we look at a lot of healthcare coverage these days, that deductible factors very deeply into a patient’s care choices, into how they view different options offered to them. And this idea that patients can live with the fear of financial devastation and bankruptcy as part of their healthcare experience is something that has to give us a certain sense of humility, has to give us a certain sense of pause, and also I think forces us as practitioners to assume greater ownership over these sorts of ideas, which is something that frankly I hadn’t done previously.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias
July 30th 2025Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.
Read More